We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION.
- Authors
Papajik, Tomas; Pikalova, Zuzana; Raida, Ludek; Skoumalova, Ivana; Vondrakova, Jana; Faber, Edgar; Prochazka, Vit; Kubova, Zuzana; Kucerova, Ladislava; Pavlik, Tomas; Dusek, Ladislav; Indrak, Karel
- Abstract
Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/ kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179).
- Publication
Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2009, Vol 153, Issue 3, p211
- ISSN
1213-8118
- Publication type
Article
- DOI
10.5507/bp.2009.035